Nervonik closes oversubscribed $52.5M Series B for ECAP closed-loop peripheral nerve stimulation — total exceeds $65M
Summary
Nervonik closed an oversubscribed $52.5M Series B led by Amzak Health, with Elevage Medical Technologies, USVP, Lumira, Foothill, and Shangbay Capital. Total funding exceeds $65M including the March 2025 $13M Series A. The company is applying the ECAP closed-loop sensing approach — proven superior for SCS by Saluda Medical — to peripheral nerve stimulation for chronic pain. First-in-human ECAP recording from PNS leads was successfully demonstrated in 2024.
Why it matters
If ECAP-guided PNS demonstrates the same superiority over conventional PNS that Evoke demonstrated over conventional SCS, Nervonik's $65M of capital would be backing the differentiation that wins in the $2.5B+ peripheral nerve stimulation market. Amzak Health leading — a specialist healthcare fund with deep neuromodulation expertise — validates the ECAP PNS thesis at the investor level.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial